Your browser doesn't support javascript.
Airway Delivery of Hydrogel-Encapsulated Niclosamide for the Treatment of Inflammatory Airway Disease.
Ousingsawat, Jiraporn; Centeio, Raquel; Cabrita, Inês; Talbi, Khaoula; Zimmer, Oliver; Graf, Moritz; Göpferich, Achim; Schreiber, Rainer; Kunzelmann, Karl.
  • Ousingsawat J; Physiological Institute, University of Regensburg, University Street 31, 93040 Regensburg, Germany.
  • Centeio R; Physiological Institute, University of Regensburg, University Street 31, 93040 Regensburg, Germany.
  • Cabrita I; Physiological Institute, University of Regensburg, University Street 31, 93040 Regensburg, Germany.
  • Talbi K; Physiological Institute, University of Regensburg, University Street 31, 93040 Regensburg, Germany.
  • Zimmer O; Department of Pharmaceutical Technology, University of Regensburg, 93040 Regensburg, Germany.
  • Graf M; Department of Pharmaceutical Technology, University of Regensburg, 93040 Regensburg, Germany.
  • Göpferich A; Department of Pharmaceutical Technology, University of Regensburg, 93040 Regensburg, Germany.
  • Schreiber R; Physiological Institute, University of Regensburg, University Street 31, 93040 Regensburg, Germany.
  • Kunzelmann K; Physiological Institute, University of Regensburg, University Street 31, 93040 Regensburg, Germany.
Int J Mol Sci ; 23(3)2022 Jan 19.
Article in English | MEDLINE | ID: covidwho-1625612
ABSTRACT
Repurposing of the anthelminthic drug niclosamide was proposed as an effective treatment for inflammatory airway diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease. Niclosamide may also be effective for the treatment of viral respiratory infections, such as SARS-CoV-2, respiratory syncytial virus, and influenza. While systemic application of niclosamide may lead to unwanted side effects, local administration via aerosol may circumvent these problems, particularly when the drug is encapsulated into small polyethylene glycol (PEG) hydrospheres. In the present study, we examined whether PEG-encapsulated niclosamide inhibits the production of mucus and affects the pro-inflammatory mediator CLCA1 in mouse airways in vivo, while effects on mucociliary clearance were assessed in excised mouse tracheas. The potential of encapsulated niclosamide to inhibit TMEM16A whole-cell Cl- currents and intracellular Ca2+ signalling was assessed in airway epithelial cells in vitro. We achieved encapsulation of niclosamide in PEG-microspheres and PEG-nanospheres (Niclo-spheres). When applied to asthmatic mice via intratracheal instillation, Niclo-spheres strongly attenuated overproduction of mucus, inhibited secretion of the major proinflammatory mediator CLCA1, and improved mucociliary clearance in tracheas ex vivo. These effects were comparable for niclosamide encapsulated in PEG-nanospheres and PEG-microspheres. Niclo-spheres inhibited the Ca2+ activated Cl- channel TMEM16A and attenuated mucus production in CFBE and Calu-3 human airway epithelial cells. Both inhibitory effects were explained by a pronounced inhibition of intracellular Ca2+ signals. The data indicate that poorly dissolvable compounds such as niclosamide can be encapsulated in PEG-microspheres/nanospheres and deposited locally on the airway epithelium as encapsulated drugs, which may be advantageous over systemic application.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia / Respiratory System / Niclosamide Topics: Long Covid Limits: Animals / Humans Language: English Year: 2022 Document Type: Article Affiliation country: Ijms23031085

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia / Respiratory System / Niclosamide Topics: Long Covid Limits: Animals / Humans Language: English Year: 2022 Document Type: Article Affiliation country: Ijms23031085